STOCK TITAN

MARCHEX (MCHX) SEC Filings, Apr-Jul 2026

MCHX NASDAQ

Marchex, Inc. filings document the regulatory record for a Delaware operating company that provides AI-based conversational intelligence and analytics solutions. Its disclosures cover operating and financial results, material agreements, capital-structure matters, governance actions, legal proceedings, and risk factors tied to its conversational analytics business.

Recent filings include Form 8-K material-event reports, proxy materials for annual meeting matters, and compensation disclosures involving cash awards, restricted stock units, stock options, and the 2021 Stock Incentive Plan. The filings also describe the company's Class A and Class B common stock voting structure, board and stockholder voting matters, lease-related agreements and impairments, and settlement documentation for civil litigation.

Rhea-AI Summary

Marchex, Inc. reported that vice chairman Michael A. Arends acquired $4,144,144 of 6.0% convertible debt due 2028 from the company in connection with Marchex’s purchase of 100% of Archenia, Inc.

The notes pay 6% interest in three equal principal tranches on the 12-, 18- and 24‑month anniversaries of the July 1, 2026 closing. They are convertible, in whole or in part, into Class B common stock at $1.80 per share, covering 2,302,302 underlying shares.

The stock purchase agreement also grants Arends an earn-out right to receive up to 828,829 additional shares for each of the first and second 12‑month periods after closing if Archenia’s revenue or Adjusted EBITDA exceed prior‑period levels and it meets specified integration or customer retention targets. The right to receive these additional shares became fixed and irrevocable on the closing date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
insider
-
Rhea-AI Summary

Marchex, Inc. completed its acquisition of Archenia, Inc., a performance-based marketing technology company that uses AI, natural-language analytics and automated decisioning to deliver high-intent consumer interactions to advertisers.

As consideration, Marchex issued an aggregate of $10 million in convertible promissory notes to the sellers, including its Chairman and Vice Chairman. The Notes bear 6% interest, are payable in three equal tranches on the 12-, 18- and 24‑month anniversaries of the closing, and are convertible into Class B common stock at $1.80 per share.

Marchex may also issue up to 4 million Class B shares in earn-out consideration, in two blocks of 2 million shares each, if Archenia exceeds prior‑year revenue or Adjusted EBITDA and meets specified integration and customer retention targets in each of the first two 12‑month periods after closing. Stockholders strongly approved the transaction, with approximately 99.9% support under both required vote standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
current report
-
Rhea-AI Summary

Marchex, Inc. is asking holders to approve a proposed acquisition of Archenia, Inc. at a Special Meeting on July 1, 2026.

The Purchase Price consists of an aggregate $10,000,000 in convertible promissory notes bearing 6% interest (convertible into Class B shares at $1.80 per share) and potential Earn-out Consideration of 2,000,000 shares of Class B common stock for each of the first and second 12-month performance periods following closing. The Sellers include Chairman Russell C. Horowitz and Vice Chairman Michael Arends; a Special Committee of independent directors negotiated the Transaction and the Board unanimously recommends approval.

Stockholder approval requires (a) a majority of voting power of all issued and outstanding Class A and Class B shares and (b) a Majority of the Minority Vote disregarding shares owned by Horowitz and Arends; on the record date there were 4,660,927 Class A shares and 39,660,339 Class B shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
proxy
Rhea-AI Summary

Marchex, Inc. is asking stockholders to approve its acquisition of Archenia, Inc., with consideration including $10.0 million in convertible promissory notes and potential 2,000,000 Class B shares per 12‑month performance period as earn‑outs.

The notes bear 6% interest, pay in three tranches at 12/18/24 months and are convertible at $1.80 per Class B share; earn‑out issuances depend on revenue or Adjusted EBITDA and specified integration or customer retention targets. Closing is conditioned on stockholder approval (including a Majority of the Minority Vote) and other closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
proxy
-
Rhea-AI Summary

Marchex, Inc. reported a smaller loss while revenue declined for the quarter ended March 31, 2026. Revenue was $10.6 million, down from $11.4 million a year earlier, and net loss narrowed to $1.7 million, or $0.04 per share for both Class A and B.

Cash and cash equivalents were $9.0 million, with total assets of $38.5 million and stockholders’ equity of $28.9 million. Operating cash outflow improved to $0.5 million from $2.6 million as working-capital swings moderated.

The company recorded a $0.2 million impairment tied to subleasing its Seattle headquarters and finalized a $2.1 million settlement related to the Telmetrics acquisition, payable through 2027. Marchex also signed a stock purchase agreement to acquire Archenia, Inc. for $10.0 million in 6% convertible notes plus up to 4.0 million Class B earnout shares, subject to approval by disinterested stockholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
quarterly report
-
Rhea-AI Summary

Marchex, Inc. reported first quarter 2026 results and outlined plans to acquire Archenia, Inc. Revenue was $10.6 million, down from $11.4 million a year earlier. Net loss narrowed to $1.7 million or $(0.04) per diluted share, versus a $2.0 million loss or $(0.05) per share in 2025.

Adjusted EBITDA was a loss of $0.1 million, improving from a $0.8 million loss; excluding $0.7 million of reorganization and acquisition costs, Adjusted EBITDA would have been a $0.6 million gain. For Q2 2026, Marchex anticipates sequential revenue growth and projects Adjusted EBITDA of $1.6–$1.8 million, with potential to reach about $2 million in Q3 on a stand-alone basis and $2.5 million with Archenia.

Marchex entered a Stock Purchase Agreement to acquire 100% of Archenia, a performance-based, AI-driven customer acquisition company, subject to approval by a majority of disinterested stockholders and other closing conditions. Marchex estimates the combined business could reach an annualized revenue run rate of about $60 million with Adjusted EBITDA margins of 10% or more in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
current report
Rhea-AI Summary

Marchex, Inc. has signed a Stock Purchase Agreement to acquire 100% of Archenia, Inc. for a base consideration of $10 million in convertible promissory notes. The notes carry 6% interest, are payable in three equal tranches over 12, 18 and 24 months after closing, and are convertible into Class B common stock at $1.80 per share.

Marchex may also issue up to 4 million additional Class B shares as earn-out consideration, with 2 million shares potentially issuable for each of the first two 12‑month periods after closing if Archenia exceeds prior‑period revenue or Adjusted EBITDA and meets integration and customer retention targets. The transaction requires approval by a majority of disinterested stockholders and other closing conditions, and was approved by a special committee of independent directors, which obtained a fairness opinion on the purchase price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
current report
-
Rhea-AI Summary

Marchex, Inc. entered into a Sublease Agreement with RentSpree, Inc. for its 12,300 square foot office space at 1200 5th Avenue, Suite 1300, Seattle, Washington. The term runs from May 1, 2026 through September 28, 2027.

RentSpree will pay fixed monthly rent over the term totaling approximately $337,000, with an initial rate of $19.25 per square foot, increasing after 12 months to $19.50 per square foot. In connection with this sublease, Marchex determined that the carrying value of its right‑of‑use asset for the space exceeds its estimated fair value and will record a noncash impairment charge of approximately $203,000 in its consolidated statement of operations for the quarter ending March 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
-
Rhea-AI Summary

Marchex, Inc. filed Amendment No. 1 to its annual report to add Part III disclosures on directors, executive officers, compensation, ownership and auditor fees instead of incorporating a future proxy statement by reference. The filing details a five-member board, committee structures, and independence determinations.

Marchex highlights a strong 2023 say-on-pay result, with about 95% of votes supporting named executive officer pay, and continues its mix of salary, bonus and equity awards under the 2021 Stock Incentive Plan. In 2025, President & CRO Troy Hartless received total compensation of $1,230,833, while former CEO Edwin Miller received $857,340.

The company reports dual-class equity with 4,660,927 Class A and 39,636,247 Class B shares outstanding as of April 10, 2026, and notes that directors and executives as a group control 78.5% of total voting power. For 2025, Marchex recorded a net loss of $5,235K and paid $606,890 in audit fees to RSM US LLP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
annual report
Rhea-AI Summary

Marchex, Inc. entered into a Settlement Agreement to resolve the civil action Chris Barnard and Sinc McEvenue v. Marchex, Inc. previously disclosed in its 2025 Form 10-K. The agreement covers the expected settlement amount already accrued in the 2025 consolidated financial statements.

Under the agreement, Marchex will pay $750,000 and allow the release of $250,000 held in escrow on or before May 14, 2026, followed by payments of $500,000 on November 16, 2026 and May 17, 2027, resolving all claims related to this matter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
current report

FAQ

How many MARCHEX (MCHX) SEC filings are available on StockTitan?

StockTitan tracks 48 SEC filings for MARCHEX (MCHX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MARCHEX (MCHX)?

The most recent SEC filing for MARCHEX (MCHX) was filed on July 1, 2026.